113079-60-0Relevant articles and documents
An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus
Watson, Keith G.,Brown, Renee N.,Cameron, Rachel,Chalmers, David K.,Hamilton, Stephanie,Jin, Betty,Krippner, Guy Y.,Luttick, Angela,McConnell, Darryl B.,Reece, Phillip A.,Ryan, Jane,Stanislawski, Pauline C.,Tucker, Simon P.,Wu, Wen-Yang,Barnard, Dale L.,Sidwell, Robert W.
, p. 3181 - 3184 (2003)
A series of capsid-binding compounds was screened against human rhinovirus (HRV) using a CPE based assay. The ethyl oxime ether 14 was found to have outstanding anti-HRV activity (median IC50 4.75 ng/mL), and unlike the equivalent ethyl ester c
Hydroxy- or methoxy-substituted benzaldoximes and benzaldehyde-O-alkyloximes as tyrosinase inhibitors
Ley, Jakob P,Bertram, Heinz-Jürgen
, p. 1879 - 1885 (2007/10/03)
Several benzaldoximes, benzaldehyde-O-ethyloximes, and acetophenone-oximes were synthesized and evaluated as tyrosinase inhibitors by an assay based on tyrosinase catalyzed L-DOPA oxidation. Whereas benzaldoxime itself is only a weak inhibitor, its deriva